MedTech  company uses machine

intelligence to enable precision

medicine for cardiovascular disease



Interview posted: April 20, 2020


Elucid Bioimaging, led by CBS ’17 alumnus Blake Richards, is seeking to eliminate unnecessary, invasive diagnostics and support better health outcomes for patients around the globe.


CBSACNY: What led Elucid to focus on cardiovascular disease?
Research for what is now Elucid began with academics in Boston in the early 2000s seeking to better understand what was truly causing cardiovascular events to enable both prediction and prevention. Our President and CTO Andrew Buckler, having spent 30+ years launching 3D imaging platforms, joined the team with the goal of translating this research into a commercial diagnostic. Cardiovascular disease is the number one cause of death in nearly all developed countries, yet we’re still using decades-old diagnostics that have not simply kept pace with innovation in available treatments. We see an opportunity here to have a substantial impact on global health.

CBSACNY: What problem are you solving?
Generally, patients with suspected coronary artery disease undergo a stress test or CT scan as a first line diagnostic. If the result is positive or neutral, they are sent for an invasive, $2,600+ catheter-based diagnostic to determine if revascularization (stenting) is needed. The problem is over 40% of these patients end up not requiring revascularization and even after the invasive test there is little information given about which therapeutic treatment might be best. This results in billions of unnecessary costs to the healthcare system each year and potentially avoidable patient events, including heart attacks.

CBSACNY: What does your technology do?
Our software uses machine intelligence to analyze a routinely available (non-invasive) CT scan to perform the same measurement done during the catheter-based diagnostic (FFR). This not only reduces cost and patient burden, but also provides the physician with unique information regarding the patient’s disease category and risk of the event, informing personalized treatment. All of this will be done using our on-site deployed software, seamlessly integrated into the physician’s workflow while the patient is still at the facility. Each analysis is reimbursed over $950 by most payers, including Medicare. We have had very promising results from our initial study and are on the path towards FDA-clearance.

CBSACNY: Where are you going next?
Commercialization of the current technology is our first and foremost priority, but we have a significant opportunity to expand our existing technology to truly personalize patient care in a way that has never been done before for cardiovascular disease. These results will be published soon, so I will leave it at that for now.

CBSACNY: How are you funded?
We have not received any institutional capital to this point but are starting a raise to take this technology to market. Thus far we have been funded by founder investment, an angel investor, and $6M in non-dilutive grants from the NIH and NSF.


Blake Richard’s contact info and phone numbers are in the database of the alumni club, or feel free to message him at blake.richards@elucidbio.com


Abbreviated bios of the founders:


Andrew Buckler
President & CTO, Elucid Bioimaging
CEO, Buckler Biomedical
R&D Director Imaging Systems, Philips
R&D Project Manager, HP
R&D Project Manager, Siemens

Lehigh University, BS '84
University of Rochester, MS ‘89


Blake Richards
CEO, Elucid Bioimaging
Manager - MedTech and Provider Strategy, Deloitte Consulting
Strategic Advisor - various AI-driven MedTech Startups
Director of Patient Confidentiality – Epic Systems

Duke University, BS '11
Columbia Business School, MBA ‘17